Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Exelixis (NASDAQ:EXEL) had its price objective increased by research analysts at Wells Fargo & Company from $30.00 to $35.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 18.03% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. Zacks Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of Exelixis in a research report on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Stifel Nicolaus lifted their price objective on shares of Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, Wolfe Research initiated coverage on shares of Exelixis in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $47.11.

Exelixis Trading Down 0.6%

NASDAQ:EXEL opened at $42.70 on Wednesday. Exelixis has a 12 month low of $32.38 and a 12 month high of $49.62. The firm’s 50 day moving average is $43.63 and its 200 day moving average is $40.95. The stock has a market capitalization of $11.09 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the business posted $0.55 earnings per share. Research analysts predict that Exelixis will post 2.04 earnings per share for the current year.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 72,230 shares of company stock valued at $3,046,923. 2.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Richardson Financial Services Inc. lifted its position in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 292 shares during the last quarter. Anchor Investment Management LLC grew its position in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Root Financial Partners LLC bought a new position in Exelixis in the third quarter valued at $28,000. Luminist Capital LLC raised its position in Exelixis by 2,740.0% during the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 685 shares in the last quarter. Finally, Activest Wealth Management purchased a new stake in Exelixis during the fourth quarter valued at about $32,000. 85.27% of the stock is currently owned by institutional investors.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS beat and shareholder returns — Exelixis reported $0.94 EPS vs. ~$0.74 consensus and repurchased $264.5M of stock, improving profitability metrics and returning capital to shareholders. Exelixis Reports Solid Earnings
• Positive Sentiment: Zanzalintinib upside — Management is positioning for a potential 2026 launch (PDUFA Dec. 3, 2026) for zanzalintinib in colorectal cancer, which the company cites as a multi‑billion dollar peak-sales opportunity and core to its franchise growth thesis. Pipeline & Franchise Strategy
• Positive Sentiment: Analyst upward moves — Royal Bank of Canada nudged its price target to $46 (sector perform), and Barclays has also raised targets recently, signaling some analyst confidence in the growth story. Analyst Note
• Neutral Sentiment: Core revenue driver — Cabometyx remains the primary revenue engine (franchise sales cited at ~$2.12B) and management guided 2026 revenue to $2.52–2.62B excluding potential zanzalintinib sales. Growth Strategy
• Neutral Sentiment: Supporting disclosure — Full earnings call transcript, presentation and analyst writeups are available for deeper due diligence. Earnings Presentation Call Transcript
• Neutral Sentiment: Short-interest data appears anomalous (reports showing 0 shares); treat as unreliable until corrected by exchanges/clearing agents.
• Negative Sentiment: Revenue miss and conservative baseline guidance — Q4 revenue ($598.7M) came in below the ~$609M consensus and 2026 guidance excludes potential zanzalintinib revenue, creating near‑term uncertainty and prompting profit-taking. Zacks Earnings Coverage
• Negative Sentiment: Mixed analyst stance — Wells Fargo raised its target to $35 but maintains an Equal Weight stance, which implies limited near‑term upside and contrasts with higher targets from other shops; this divergence contributes to volatile near-term sentiment. Wells Fargo Note

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.